Johnson & Johnson Working On Next-Generation Vaccine Against Variants

Johnson & Johnson
Alexander Tolstykh / Shutterstock.com

Johnson & Johnson said it was working on next-generation COVID-19 vaccines against the various variants of the coronavirus, according to Reuters.

“We could be in a situation where you could either need a booster to maintain the durability (of protection against the virus) or you might need to have a next derivative of the current vaccine to address these variants as they develop,” Johnson and Johnson CEO Alex Gorsky said at a webinar by the Economic Club of New York this week, per Reuters.

See: Moderna Starts COVID Vaccine Trial in Children, Stock Soars
Find: Should You Invest In Vaccine Stocks Right Now?

The Food and Drug Administration granted Johnson & Johnson an emergency use authorization (EUA) in February. Johnson & Johnson’s candidate, the Janssen Biotech Inc. COVID-19 vaccine, is the third vaccine being granted an EUA and the first one requiring only one dose, facilitating and accelerating distribution amidst a rollout that has been less than seamless.

Data the company released shows that its vaccine candidate is 66% effective globally and 72% effective in the U.S. at preventing moderate-to-severe COVID-19 cases, according to FDA data. In comparison, the Moderna vaccine has a 94.1% efficacy rate, while the Pfizer vaccine has a 95% efficacy rate, according to the Centers for Disease Control and Prevention.

Make Your Money Work for You
Sponsors of

See: Who Is Getting Vaccines? Survey Notes Income Disparity in Vaccine Recipients
Find: IBM and Moderna Say Their New COVID Passport Is Your Ticket to Normal Life — Others Call It a Hacker’s Paradise

It’s important to note, however, that the Moderna and Pfizer trials were conducted before the emergence of different strains, such as the strain found in South Africa. Meanwhile, Johnson & Johnson’s trial was conducted in South Africa, which may have lowered the overall efficacy rate, according to The Wall Street Journal.

Earlier this month, President Biden announced the “type of collaboration between companies we saw in World War II,” as Merck will help Johnson & Johnson produce its COVID-19 vaccine, bringing the country “on track to have enough vaccine supply for every adult in America by the end of May.”

“And with the urging and assistance of my administration, Johnson & Johnson is also taking additional new actions to safely accelerate vaccine production. Johnson & Johnson’s vaccine manufacturing facilities will now begin to operate 24/7,” Biden said in a briefing at the time.

More From GOBankingRates

Make Your Money Work for You
Sponsors of

About the Author

Yaël Bizouati-Kennedy is a former full-time financial journalist and has written for several publications, including Dow Jones, The Financial Times Group, Bloomberg and Business Insider. She also worked as a vice president/senior content writer for major NYC-based financial companies, including New York Life and MSCI. Yaël is now freelancing and most recently, she co-authored  the book “Blockchain for Medical Research: Accelerating Trust in Healthcare,” with Dr. Sean Manion. (CRC Press, April 2020) She holds two master’s degrees, including one in Journalism from New York University and one in Russian Studies from Université Toulouse-Jean Jaurès, France.

Johnson & Johnson Working On Next-Generation Vaccine Against Variants
Close popup livericher_png

We're here to help you Live Richer.

Sign up to receive our daily weekday newsletter with the latest finance and lifestyle content.

Loading...
Please enter an email.
Please enter a valid email address.
There was an unknown error. Please try again later.

For our full Privacy Policy, click here.